Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer

Propanc Biopharma, Inc. (Nasdaq: PPCB) has announced new preclinical research indicating that its pancreatic proenzyme formulation, PRP, may serve as a potential strategy to combat chemotherapy resistance in pancreatic cancer. This research was conducted in collaboration with the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo.